Wcn24-1328 the Administration of Extracellular Vesicles Derived From Mesenchymal Stem Cells Promoted Significant Renoprotection in a Severe Experimental CKD Model

Chronic kidney disease (CKD) is an important health problem worldwide. Hyperactivity of the renin-angiotensin-aldosterone system (RAAS) directly contributes to CKD progression, leading to tissue fibrosis and renal function loss. RAAS inhibitors, are the most employed drugs to the management of CKD progression, inducing effective proteinuria reduction. However, it results in only partial renoprotection. In this context, the administration of mesenchymal stem cells (mSC) to control inflammation, renal fibrosis and CKD progression has shown promising results in studies with animal models of CKD.